Adam Pearson

Oncology

At JPM2026, Astellas' chief strategy officer Adam Pearson walked pharmaphorum through the company’s four-pillared R&D strategy.

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.